Can you reduce your AGE?. Strategies to prevent AGE accumulation in diabetes

Drug Discovery Today: Therapeutic Strategies

Volumn 4, Issue 1, 2007, Pages 85-92

  Coughlan, Melinda T ^a   Cooper, Mark E ^a   Thomas, Merlin C ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2 ISOPROPYLIDENEHYDRAZONO 4 OXO 5 THIAZOLIDINYLACETANILIDE; 4 AMINOBENZOIC ACID; ACETYLCYSTEINE; ADVANCED GLYCATION END PRODUCT; ALAGEBRIUM; ALPHA TOCOPHEROL; AMINOGUANIDINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIOXIDANT; ASCORBIC ACID; BENFOTIAMINE; BENZOIC ACID; COCARBOXYLASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INOSITOL; MESALAZINE; METFORMIN; OLMESARTAN; PERINDOPRIL; PIOGLITAZONE; PLACEBO; PROBUCOL; PYRIDOXAMINE; SALICYLIC ACID; TAURINE; TEMOCAPRILAT; THIAMINE; THIOCTIC ACID; TROGLITAZONE; UNINDEXED DRUG;

ALBUMINURIA; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; GLYCEMIC CONTROL; HEART FAILURE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; LIPID PEROXIDATION; NONHUMAN; OXIDATIVE STRESS; RENAL PROTECTION; REVIEW; SIDE EFFECT;

EID: 37249051801     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2007.07.003     Document Type: Review

References (50)

1. Brownlee M., et al. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 232 (1986) 1629-1632
2. Monnier V.M., et al. Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Control and Complications Trial. Diabetes 48 (1999) 870-880
3. Forbes J.M., et al. Role of advanced glycation end products in diabetic nephropathy. J. Am. Soc. Nephrol. 14 Suppl. 3 (2003) S254-S258
4. Yim M.B., et al. Protein glycation: creation of catalytic sites for free radical generation. Ann. N. Y. Acad. Sci. 928 (2001) 48-53
5. Genuth S., et al. Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes. Diabetes 54 (2005) 3103-3111
6. Booth A.A., et al. In vitro kinetic studies of formation of antigenic advanced glycation end products (AGEs). Novel inhibition of post-Amadori glycation pathways. J. Biol. Chem. 272 (1997) 5430-5437
7. Monnier V.M., et al. Glycation products as markers and predictors of the progression of diabetic complications. Ann. N. Y. Acad. Sci. 1043 (2005) 567-581
8. Thornalley P.J., et al. Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem. J. 344 Pt 1 (1999) 109-116
9. Ahmed N., et al. Peptide mapping identifies hotspot site of modification in human serum albumin by methylglyoxal involved in ligand binding and esterase activity. J. Biol. Chem. 280 (2005) 5724-5732
10. Soulis-Liparota T., et al. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes 40 (1991) 1328-1334
11. Bolton W.K., et al. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am. J. Nephrol. 24 (2004) 32-40
12. Forbes J.M., et al. Renoprotective effects of a novel inhibitor of advanced glycation. Diabetologia 44 (2001) 108-114
13. Wilkinson-Berka J.L., et al. ALT-946 and aminoguanidine, inhibitors of advanced glycation, improve severe nephropathy in the diabetic transgenic (mREN-2)27 rat. Diabetes 51 (2002) 3283-3289
14. Miyoshi H., et al. Aminoguanidine pyridoxal adduct is superior to aminoguanidine for preventing diabetic nephropathy in mice. Horm. Metab. Res. 34 (2002) 371-377
15. Miyata T., et al. Mechanism of the inhibitory effect of OPB-9195 [(+/-)-2-isopropylidenehydrazono-4-oxo-thiazolidin-5-yla cetanilide] on advanced glycation end product and advanced lipoxidation end product formation. J. Am. Soc. Nephrol. 11 (2000) 1719-1725
16. Tsuchida K., et al. Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195. Diabetologia 42 (1999) 579-588
17. Yamamoto Y., et al. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J. Clin. Invest. 108 (2001) 261-268
18. Figarola J.L., et al. LR-90 a new advanced glycation endproduct inhibitor prevents progression of diabetic nephropathy in streptozotocin-diabetic rats. Diabetologia 46 (2003) 1140-1152
19. Ruggiero-Lopez D., et al. Reaction of metformin with dicarbonyl compounds. Possible implication in the inhibition of advanced glycation end product formation. Biochem. Pharmacol. 58 (1999) 1765-1773
20. Forbes J.M., et al. Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes 51 (2002) 3274-3282
21. Miyata T., et al. Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. J. Am. Soc. Nephrol. 13 (2002) 2478-2487
22. Voziyan P.A., and Hudson B.G. Pyridoxamine: the many virtues of a maillard reaction inhibitor. Ann. N. Y. Acad. Sci. 1043 (2005) 807-816
23. Alderson N.L., et al. The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats. Kidney Int. 63 (2003) 2123-2133
24. Williams M.E. Clinical studies of advanced glycation end product inhibitors and diabetic kidney disease. Curr. Diab. Rep. 4 (2004) 441-446
25. Babaei-Jadidi R., et al. Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. Diabetes 52 (2003) 2110-2120
26. Liu J., et al. Glycation end-product cross-link breaker reduces collagen and improves cardiac function in aging diabetic heart. Am. J. Physiol. Heart Circ. Physiol. 285 (2003) H2587-H2591
27. Peyroux J., and Sternberg M. Advanced glycation endproducts (AGEs): Pharmacological inhibition in diabetes. Pathol. Biol. (Paris) 54 (2006) 405-419
28. Davies G.F., et al. Inhibition of phosphoenolpyruvate carboxykinase (PEPCK) gene expression by troglitazone: a peroxisome proliferator-activated receptor-gamma (PPARgamma)-independent, antioxidant-related mechanism. Biochem. Pharmacol. 62 (2001) 1071-1079
29. Cooper G.J., et al. Regeneration of the heart in diabetes by selective copper chelation. Diabetes 53 (2004) 2501-2508
30. Price D.L., et al. Chelating activity of advanced glycation end-product inhibitors. J. Biol. Chem. 276 (2001) 48967-48972
31. Brownlee M., et al. Nonenzymatic glycosylation and the pathogenesis of diabetic complications. Ann. Intern. Med. 101 (1984) 527-537
32. Vasan S., et al. An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature 382 (1996) 275-278
33. Thallas-Bonke V., et al. Attenuation of extracellular matrix accumulation in diabetic nephropathy by the advanced glycation end product cross-link breaker ALT-711 via a protein kinase C-alpha-dependent pathway. Diabetes 53 (2004) 2921-2930
34. Forbes J.M., et al. The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. FASEB. J. 17 (2003) 1762-1764
35. Coughlan M.T., et al. Combination therapy with the advanced glycation end product cross-link breaker, alagebrium, and angiotensin converting enzyme inhibitors in diabetes: synergy or redundancy?. Endocrinology 148 (2007) 886-895
36. Kass D.A., et al. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation 104 (2001) 1464-1470
37. Bakris G.L., et al. Advanced glycation end-product cross-link breakers. A novel approach to cardiovascular pathologies related to the aging process. Am. J. Hypertens. 17 12 Pt 2 (2004) 23S-30S
38. Wendt T.M., et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am. J. Pathol. 162 (2003) 1123-1137
39. Park L., et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat. Med. 4 (1998) 1025-1031
40. Forbes J.M., et al. Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. J. Am. Soc. Nephrol. 16 (2005) 2363-2372
41. Li Y.M., et al. Antibacterial activity of lysozyme and lactoferrin is inhibited by binding of advanced glycation-modified proteins to a conserved motif. Nat. Med. 1 (1995) 1057-1061
42. Zheng F., et al. Lysozyme enhances renal excretion of advanced glycation endproducts in vivo and suppresses adverse age-mediated cellular effects in vitro: a potential AGE sequestration therapy for diabetic nephropathy?. Mol. Med. 7 (2001) 737-747
43. Li J.H., et al. Advanced glycation end products induce tubular epithelial-myofibroblast transition through the RAGE-ERK1/2 MAP kinase signaling pathway. Am. J. Pathol. 164 (2004) 1389-1397
44. Flyvbjerg A., et al. Long-term renal effects of a neutralizing RAGE antibody in obese type 2 diabetic mice. Diabetes 53 (2004) 166-172
45. Jensen L.J., et al. Renal effects of a neutralising RAGE-antibody in long-term streptozotocin-diabetic mice. J. Endocrinol. 188 (2006) 493-501
46. Zheng F., et al. Prevention of diabetic nephropathy in mice by a diet low in glycoxidation products. Diabetes. Metab. Res. Rev. 18 (2002) 224-237
47. Uribarri J., et al. Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients. J. Am. Soc. Nephrol. 14 (2003) 728-731
48. Vlassara H., et al. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 15596-15601
49. Khalifah R.G., et al. Post-Amadori AGE inhibition as a therapeutic target for diabetic complications: a rational approach to second-generation Amadorin design. Ann. N. Y. Acad. Sci. 1043 (2005) 793-806
50. Goldberg T., et al. Advanced glycoxidation end products in commonly consumed foods. J. Am. Diet. Assoc. 104 (2004) 1287-1291